Tech Company Financing Transactions
Kymab Funding Round
On 11/28/2016, Kymab raised $100 million in Series C funding from ORI Healthcare Fund, Bill & Melinda Gates Foundation and Malin.
Transaction Overview
Company Name
Announced On
11/28/2016
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series C
Investors
Proceeds Purpose
The Company currently has 12 pre-clinical programs under development that are with a strong focus on immuno-oncology while also covering hematology, autoimmune disease and infectious disease. The scientific and research efforts are led by teams of world-class scientists and industry veterans. The Company will continue to build a strong pipeline of antibody candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
The Bennet Building (B930) Babraham Research Campus
Cambridge, CB22 3AT
UK
Cambridge, CB22 3AT
UK
Phone
Website
Email Address
Overview
Our unique technologies drive our rapid development of effective, human antibodies across our four main therapeutic areas - immuno-oncology, inflammation, haematology and infectious disease.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Simon Sturge
Chief Financial Officer
Anne Hyland
Chief Medical Officer
Sonia Quaratino
Chief Operating Officer
Glenn Friedrich
Chief Scientific Officer
Allan Bradley
VP - Bus. Development
Nigel Clark
VP - General Counsel
Jasper Clube
Browse more venture capital transactions:
Prev: 11/28/2016: Cerahelix venture capital transaction
Next: 11/28/2016: Fullbridge venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs